上海莱士 (002252)

Shanghai RAAS Blood Products Co.,Ltd.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexMSCI Mid Cap IndexSpecial Purpose LoansMid Cap GrowthCSI 100 IndexCSI 200 IndexCSI A100 IndexInnovative DrugsBroker Heavy PositionsPharmaceutical ManufacturingSynthetic BiologyGuozheng Growth IndexCSI 300 IndexMargin Trading and Securities LendingIndustry LeadersNon-Cyclical StocksSME & ChiNext 100 IndexSME 100 IndexSME 300 IndexSZSE 100 IndexSZSE 300 IndexSZSE 50 IndexSZSE Growth Index

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 663798.48
  • Circulating A-Shares(W): 663448.96
  • Earnings Per Share(RMB): 0.2220
  • Net Assets Per Share(RMB): 4.9087
  • Operating Revenue(W RMB): 609105.66
  • Total Profit(W RMB): 172372.25
  • Net Profit Attributable to Parent(W RMB): 147073.90
  • Net Profit Growth Rate(%): -19.97
  • Weighted Return on Equity(%): 4.5500
  • Operating Cash Flow Per Share(RMB): 0.1040
  • Undistributed Profit Per Share(RMB): 1.6835
  • Capital Reserve Per Share(RMB): 2.1146

2. Main Business

The main business covers:

  • Production and sales of blood products

3. Company Basic Information

  • Company Name: Shanghai RAAS Blood Products Co., Ltd.
  • Listing Date: 2008-06-23
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 2009 Wangyuan Road, Fengxian District, Shanghai, China
  • Website: www.raas-corp.com
  • Company Profile: The company is a foreign-invested joint-stock company established through the overall transformation of Shanghai RAAS Blood Products Co., Ltd., approved by the Ministry of Commerce of the People's Republic of China (Document No. Shang Zi Pi [2007] No. 17). It obtained the "Approval Certificate for Enterprises with Investment from Taiwan, Hong Kong, Macao and Overseas Chinese" (No. Shang Wai Zi Zi Shen A Zi [2007] No. 0006) on January 18, 2007. The company obtained its amended Business License on March 1, 2007.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Haiyingkang (Qingdao) Medical Technology Co., Ltd. General Legal Person 154751.34 23.33
2 GRIFOLS,S.A. General Legal Person 43706.97 6.59
3 China CITIC Financial Asset Management Co., Ltd. General Legal Person 31411.84 4.73
4 China Cinda Asset Management Co., Ltd. General Legal Person 27920.67 4.21
5 Huabao Trust Co., Ltd. - Huabao-CITIC No.1 Single Fund Trust Asset Management Plan 26809.00 4.04
6 RAAS CHINA LIMITED General Legal Person 15384.91 2.32
7 Huaxin International Trust Co., Ltd. - Huaxin Trust · Wealth Growth Phase V Single Fund Trust Asset Management Plan 13970.00 2.11
8 CITIC Securities Co., Ltd. Broker 12439.27 1.87
9 Hong Kong Securities Clearing Company Ltd. Northbound Capital 9932.04 1.50
10 Huatai-PineBridge CSI 300 Exchange Traded Fund Fund 9036.87 1.36

5. Concept Sectors

  • Innovative Drugs
  • Synthetic Biology
  • Margin Trading & Securities Lending
  • Heavily Held by Brokers
  • Industry Leader
  • MSCI Mid Cap
  • Non-Cyclical Stocks
  • Special Loans
  • CSI 100
  • CSI SME 100
  • SZSE SME 100
  • Mid Cap Growth
  • SZSE 100
  • SZSE 300
  • SZSE Growth
  • SZSE Growth Index
  • CSI 300
  • CSI SME 300
  • CSI 200
  • CSI 300 Non-Cyclical
  • CSI 300 ESG
  • SZSE 50
  • CSI A100

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information